Нефролитиаз при первичном гиперпаратиреозе, современный взгляд

Первичный гиперпаратиреоз (ПГПТ) в последние годы привлекает все больше внимания врачей разных специальностей. В связи с широкой распространенностью и превалированием мягкой формы возможность прогнозирования риска развития висцеральных нарушений (нефролитиаза, нефрокальциноза, сердечно-сосудистых проявлений, язвенной болезни) при ПГПТ определяет показания к консервативному ведению данной группы пациентов. Нефролитиаз является одним из классических проявлений заболевания и включен в перечень абсолютных показаний к удалению образования околощитовидных желез. Механизм развития нефролитиаза и нефрокальциноза при ПГПТ не до конца понятен, многие исследования посвящены изучению возможных предикторов их развития. В статье рассматриваются современные представления о клинических особенностях, факторах риска развития нефролитиаза у больных с ПГПТ.

1. Мокрышева НГ. Первичный гиперпаратиреоз (эпидемиология, клиника, современные принципы диагностики и лечения) (диссертация). ФГБУ Эндокринологический научный центр; 2011. [Mokrysheva NG. Pervichnyy giperparatireoz (epidemiologiya, klinika, sovremennye printsipy diagnostiki i lecheniya) [Dissertation]. Endocrinology Research Centre; 2011.].

2. Bilezikian JP. Clinical Spectrum of Primary Hyperparathyroidism. Reviews in endocrine and metabolic disorders. 2000;1(4):237-245. Available from: http://link.springer.com/10.1023/A:1026508829397 PubMed PMID: 11706737. doi: 10.1023/A:1026508829397.

3. Pallan S, Khan A. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician 2011;57(2):184-189. Available from: http://www.cfp.ca/cgi/pmidlookup?view=long&pmid=21321169 PubMed PMID: 21321169.

4. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. 2009;94(2):351-365. Available from: http://press.endocrine.org/doi/abs/10.1210/jc.2008-1760 doi: 10.1210/jc.2008-1760.

5. Mollerup CL, Lindewald H. Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. World J Surg 1999;23(2):173-175. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+7440-70-2 PubMed PMID: 9880427.

6. Mollerup CL. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002;325(7368):807. Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.325.7368.807 PubMed PMID: 12376441. doi: 10.1136/bmj.325.7368.807.

7. Söreide JA, van Heerden JA, Grant CS, Lo CY, Ilstrup DM. Characteristics of patients surgically treated for primary hyperparathyroidism with and without renal stones. Surgery 1996;120(6):1033-1038. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0039606096800511 PubMed PMID: 8957491. doi: 10.1016/S0039-6060(96)80051-1.

8. Bilezikian JP, Khan AA, Potts JT. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. The Journal of Clinical Endocrinology & Metabolism 2009;94(2):335-339. Available from: http://press.endocrine.org/doi/abs/10.1210/jc.2008-1763 PubMed PMID: 19193908. doi: 10.1210/jc.2008-1763.

9. Sneider MS, Solorzano CC, Montano RE, Anello C, Irvin GL, Lew JI. Sporadic Primary Hyperparathyroidism in Young Individuals: Different Disease and Treatment. Journal of Surgical Research 2009;155(1):100-103. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022480408005246 PubMed PMID: 19135685. doi: 10.1016/j.jss.2008.07.041.

10. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial.. J Clin Endocrinol Metab 2007;92(8):3114-3121. Available from: http://www.diseaseinfosearch.org/result/3590 PubMed PMID: 17535997. doi: 10.1210/jc.2007-0219.

11. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial.. J Clin Endocrinol Metab 2007;92(5):1687-1692. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=17284629 PubMed PMID: 17284629. doi: 10.1210/jc.2006-1836.

12. Rao, D. Sudhaker, , Phillips ER, Divine GW, Talpos GB. Randomized Controlled Clinical Trial of Surgery Versus No Surgery in Patients with Mild Asymptomatic Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism 2004;89(11):5415-5422. Available from: http://press.endocrine.org/doi/abs/10.1210/jc.2004-0028 doi: 10.1210/jc.2004-0028.

13. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.. J Clin Endocrinol Metab 2008;93(9):3462-3470. Available from: http://europepmc.org/abstract/MED/18544625 PubMed PMID: 18544625. doi: 10.1210/jc.2007-1215.

14. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.. N Engl J Med 1999;341(17):1249-1255. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199910213411701?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov PubMed PMID: 10528034. doi: 10.1056/NEJM199910213411701.

15. Bolland MJ, Grey AB, Orr-Walker BJ, Horne AM, Evans MC, Clearwater JM, et al. Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism.. N Z Med J 2008;121(1277):18-29. Available from: http://www.diseaseinfosearch.org/result/3590 PubMed PMID: 18677327.

16. Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2011;75(2):169-176. Available from: http://www.diseaseinfosearch.org/result/3590 PubMed PMID: 21158894. doi: 10.1111/j.1365-2265.2010.03958.x.

17. Пигарова ЕА. Физиология обмена кальция в почках. Ожирение и метаболизм. 2011;(4): 3-8. [Pigarova EA. Physiology of calcium metabolism in kidneys. Obes. metabol 2011;(4):3-8.] Available from: http://endojournals.ru/index.php/omet/article/view/5296 doi: 10.14341/2071-8713-5296

18. Беляева АВ, Мокрышева НГ, Рожинская ЛЯ. Концентрационная функция почек при первичном гиперпаратиреозе. Ожирение и метаболизм 2009;(1): 8-12. [Belyaeva AV, Mokrysheva NG, Rozhinskaya L. Kontsentratsionnaya funktsiya pochek pri pervichnom giperparatireoze. Obes. metabol 2009;(1):8-12. Available from: http://endojournals.ru/index.php/omet/article/view/5102 doi: 10.14341/2071-8713-5102.].

19. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism.. J Clin Endocrinol Metab 2011;96(8):2377-2385. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=21646371 PubMed PMID: 21646371. doi: 10.1210/jc.2011-0569.

20. Вороненко ИВ, Мокрышева НГ, Рожинская ЛЯ, Сыркин АЛ. Нарушения углеводного и жирового обмена при первичном гиперпаратиреозе. Ожирение и метаболизм. 2008; 4: 18-24. [Voronenko IV, Mokrysheva NG, Rozhinskaya LY, Syrkin AL. Narusheniya uglevodnogo i zhirovogo obmena pri pervichnom giperparatireoze. Obesity and metabolism 2008;4:18-24.].

21. Калинченко СА, Пигарова ЕА, Гусакова ДА, Плещеева АВ. Витамин Д и мочекаменная болезнь. Consilium Medicum. 2012; 12 (14): 97-103. [Kalinchenko SA, Pigarova EA, Gusakova DA, Pleshcheeva AV. Vitamin D i mochekamennaya bolezn'. Consilium Medicum 2012; 12 (14): 97-103].

22. Suh JM, Cronan JJ, Monchik JM. Primary Hyperparathyroidism: Is There an Increased Prevalence of Renal Stone Disease. American Journal of Roentgenology 2008;191(3):908-911. Available from: http://www.ajronline.org/doi/abs/10.2214/AJR.07.3160 doi: 10.2214/AJR.07.3160.

23. Borretta G, Gianotti L, Cesario F, Borretta V, Tassone F. Renal function in primary hyperparathyroidism. G Ital Nefrol 2010;27 Suppl 50:91-5. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=20922703 PubMed PMID: 20922703.

24. Hedback G, Oden A. Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Invest 1998;28(12):1011-1018. Available from: http://doi.wiley.com/10.1046/j.1365-2362.1998.00387.x doi: 10.1046/j.1365-2362.1998.00387.x.

25. Yamashita H, Noguchi S, Uchino S, Watanabe S, Murakami T, Ogawa T, et al. Influence of renal function on clinico-pathological features of primary hyperparathyroidism. European Journal of Endocrinology 2003;148(6):597-602. Available from: http://www.eje-online.org/cgi/doi/10.1530/eje.0.1480597 PubMed PMID: 12773130. doi: 10.1530/eje.0.1480597.

26. Tassone F, Gianotti L, Emmolo I, Ghio M, Borretta G. Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism.. J Clin Endocrinol Metab 2009;94(11):4458-4461. Available from: http://www.diseaseinfosearch.org/result/3590 PubMed PMID: 19808852. doi: 10.1210/jc.2009-0587.

27. Lin Y, Mao Q, Zheng X, Chen H, Yang K, Xie L. Vitamin D receptor genetic polymorphisms and the risk of urolithiasis: a meta-analysis. Urol Int 2011;86(3):249-255. PubMed PMID: 21325790. doi: 10.1159/000323949.

28. Hedbäck GM, Odén AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. Eur J Clin Invest 2002;28(12):1011-1018. Available from: http://doi.wiley.com/10.1046/j.1365-2362.1998.00387.x PubMed PMID: 12028502. doi: 10.1046/j.1365-2362.1998.00387.x.

29. Kashitani T, Makino H, Nagake Y, Hironaka K, Shikata K, Ogura T, et al. Two cases of hypercalcemic nephropathy associated with primary hyperparathyroidism. Nihon Jinzo Gakkai Shi 1993;35(10):1189-1194. PubMed PMID: 8264108.

30. Hedbäck G, Abrahamsson K, Odén A. The improvement of renal concentration capacity after surgery for primary hyperparathyroidism. Eur J Clin Invest 2001;31(12):1048-1053. Available from: http://www.diseaseinfosearch.org/result/3590 PubMed PMID: 11903490.

31. Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh Q, Stoller ML. Patients with primary hyperparathyroidism - why do some form stones?. J Urol 2009;181(5):2141-2145. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=19296981 PubMed PMID: 19296981. doi: 10.1016/j.juro.2009.01.028.

32. Pallan SH, Rahman MO, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ. 2012;344:e1013.PubMed PMID: 22431655. doi: 10.1136/bmj.e1013.

33. Starup-Linde J, Waldhauer E, Rolighed L, Mosekilde L, Vestergaard P. Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables.. Eur J Endocrinol 2012;166(6):1093-1100. Available from: http://eje-online.org/cgi/pmidlookup?view=long&pmid=22474170 PubMed PMID: 22474170. doi: 10.1530/EJE-12-0032.

34. Wu B, Haigh PI, Hwang R, Ituarte PHG, Liu IA, Hahn TJ, et al. Underutilization of Parathyroidectomy in Elderly Patients with Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism 2010;95(9):4324-4330. Available from: http://press.endocrine.org/doi/abs/10.1210/jc.2009-2819 PubMed PMID: 20610600. doi: 10.1210/jc.2009-2819.

35. Дзеранов НК, Рапопорт ЛМ. Литолитическая терапия. Практические рекомендации: Москва; 2011. [Dzeranov NK, Rapoport LM. Litoliticheskaya terapiya. Prakticheskie rekomendatsii: Moskva; 2011].

36. Bouzidi H, Brauwere, D. de , Daudon M. Does urinary stone composition and morphology help for prediction of primary hyperparathyroidism. Nephrology Dialysis Transplantation 2011;26(2):565-572. Available from: http://ndt.oxfordjournals.org/cgi/doi/10.1093/ndt/gfq433 doi: 10.1093/ndt/gfq433.

37. Вощула В.И. Мочекаменная болезнь: этиотропное и патогенетическое лечение, профилактика. Монография: Минск; 2006. [Voshchula V.I. Mochekamennaya bolezn': etiotropnoe i patogeneticheskoe lechenie, profilaktika. Monografiya: Minsk; 2006].

38. Odvina CV, Sakhaee K, Heller HJ, Peterson RD, Poindexter JR, Padalino PK, et al. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urol Res 2007;35(3):123-128. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=17476495 PubMed PMID: 17476495. doi: 10.1007/s00240-007-0096-2.

39. Sorensen MD, Duh Q, Grogan RH, Tran TC, Stoller ML. Differences in metabolic urinary abnormalities in stone forming and nonstone forming patients with primary hyperparathyroidism. Surgery 2012;151(3):477-483. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0039606011003904 PubMed PMID: 21893327. doi: 10.1016/j.surg.2011.07.039.

40. Corbetta S, Baccarelli A, Aroldi A, Vicentini L, Fogazzi GB, Eller-Vainicher C, et al. Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest 2005;28(2):122-128. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=15887857 PubMed PMID: 15887857.

41. D'Angelo A, Lodetti MG, Giannini S, Castrignano R, al Awady M, Malvasi L, et al. Hyperparathyroidism: cause or consequence of recurrent calcium nephrolithiasis?. Miner Electrolyte Metab 1992;18(6):359-364. Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+7440-70-2 PubMed PMID: 1291857.

42. Sorensen MD, Duh Q, Grogan RH, Tran TC, Stoller ML. Urinary Parameters as Predictors of Primary Hyperparathyroidism in Patients With Nephrolithiasis. The Journal of Urology 2012;187(2):516-521. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534711052712 doi: 10.1016/j.juro.2011.10.027.

43. Vezzoli G, Terranegra A, Arcidiacono T, Soldati L. Genetics and calcium nephrolithiasis. Kidney Int 2010;80(6):587-593. Available from: http://ghr.nlm.nih.gov/gene=CASR PubMed PMID: 20962745. doi: 10.1038/ki.2010.430.

44. Мирная CC, Пигарова ЕА, Беляева АВ, Мокрышева НГ и соавторы. Роль кальций-чувствительного рецептора в поддержании системы кальциевого гемостаза Остеопороз и остеопатии 2010; 3:31-36. [Mirnaya SS, Pigarova EA, Belyaeva AV, Mokrysheva NG, Tyul'pakov AN, Rozhinskaya LY. Rol' kal'tsiy-chuvstvitel'nogo retseptora v podderzhanii sistemy kal'tsievogo gemostaza. Osteoporosis and osteopathy 2010;3:31-36.].

45. Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F, et al. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 2002;13(10):2517-2523. Available from: http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=12239240 PubMed PMID: 12239240.

46. Vezzoli G, Terranegra A, Arcidiacono T, Gambaro G, Milanesi L, Mosca E, et al. Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region. Nephrol Dial Transplant 2010;25(7):2245-2252. Available from: http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=20067903 PubMed PMID: 20067903. doi: 10.1093/ndt/gfp760.

47. Scillitani A, Guarnieri V, Battista C, De Geronimo S, Muscarella LA, Chiodini I, et al. Primary hyperparathyroidism and the presence of kidney stones are associated with different haplotypes of the calcium-sensing receptor. J Clin Endocrinol Metab 2006;92(1):277-283. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=17018660 PubMed PMID: 17018660. doi: 10.1210/jc.2006-0857.

48. Пигарова ЕА, Мирная СС, Беляева АВ, Мокрышева НГ и соавторы. Распространенность полиморфизмов кальций-чувствительного рецептора у пациентов с первичным гиперпаратиреозом. Всероссийская конференция «Алмазовские чтения 2011»; 2011; Санкт-Петербург, Россия. [Pigarova EA, Mirnaya SS, Belyaeva AV, Mokrysheva NG i soavtory. Rasprostranennost' polimorfizmov kal'tsiy-chuvstvitel'nogo retseptora u patsientov s pervichnym giperparatireozom. Vserossiyskaya konferentsiya «Almazovskie chteniya 2011»; 2011; Sankt-Peterburg].

49. Pigarova E, Rozhinskaya L, Tiulpakov А. et al . Calcium-sensing receptor polymorphisms influence on renal calcium handling and nephrolithiasis in patients with primary hyperparathyroidism. 2012;Huston, Texas:330.

50. Karnauskas AJ, van Leeuwen JPTM, van den Bemd GCM, Kathpalia PP, DeLuca HF, Bushinsky DA, et al. Mechanism and Function of High Vitamin D Receptor Levels in Genetic Hypercalciuric Stone-Forming Rats. J Bone Miner Res 2004;20(3):447-454. Available from: http://doi.wiley.com/10.1359/JBMR.041120 doi: 10.1359/JBMR.041120.

51. Favus MJ, Karnauskas AJ, Parks JH, Coe FL. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004;89(10):4937-4943. Available from: http://www.scholaruniverse.com/ncbi-linkout?id=15472188 PubMed PMID: 15472188. doi: 10.1210/jc.2004-0412.

52. Mossetti G, Vuotto P, Rendina D, Numis FG, Viceconti R, Giordano F, et al. Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis. J Intern Med 2003;253(2):194-200. Available from: http://doi.wiley.com/10.1046/j.1365-2796.2003.01086.x PubMed PMID: 12542560. doi: 10.1046/j.1365-2796.2003.01086.x.

53. Аполихин ИО, Сивков АВ, Константинова ОВ, Сломинский ПА и соавторы. Поиск полиморфных вариантов кандидатных генов мочекаменной болезни в российской популяции. Экспериментальная и клиническая и урология. 2013;3: 56-60. [Apolikhin OI, Sivkov AV, Konstantinova OV, Slominsky PA, Kalinchenko SU. The search for the polymorphic variants of the gene candidates of urolithiasis in russian population. Experimental and clinical urology 2013;3:56-60.].